Rituximab (Rituxan).
Rituximab is a monoclonal antibody that was first approved by the FDA as an antineoplastic agent designed to treat B-cell malignancies. This article will review the mechanism of action and clinical role of this anti-B-cell agent.
Selewski
David T
DT
Division of Pediatric Nephrology, University of Michigan Mott Children's Hospital, Ann Arbor, Michigan, USA. dselewsk@med.umich.edu
Shah
G V
GV
Mody
R J
RJ
Rajdev
P A
PA
Mukherji
S K
SK
D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology; D000069283:Rituximab
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab
Blood. 1994 Oct 15;84(8):2457-66
7522629
Pediatr Hematol Oncol. 2009 Nov;26(8):566-72
19954366
Blood. 1994 Jan 15;83(2):435-45
7506951
N Engl J Med. 2002 Jan 24;346(4):235-42
11807147
Nephrology (Carlton). 2009 Oct;14(7):696-9
19796030
Lancet Oncol. 2009 Aug;10(8):816-24
19647202
N Engl J Med. 2004 Jun 17;350(25):2572-81
15201414
Blood. 2002 Feb 15;99(4):1486-8
11830505
Am J Transplant. 2006 May;6(5 Pt 1):859-66
16611321
J Clin Oncol. 1998 Aug;16(8):2825-33
9704735
J Clin Pharmacol. 2005 Jul;45(7):792-801
15951469
Br J Cancer. 2003 Oct 20;89(8):1389-94
14562003
Lancet. 2001 Nov 3;358(9292):1511-3
11705566
Blood. 2005 Feb 15;105(4):1417-23
15494430